A clinical trial to assess the intraluminal pharmacokinetics (PK) of LMN-401 in individuals with ileostomies .
To compare the intraluminal PK of tablet formulations of orally administered LMN-401 in the small intestine. To determine the safety and tolerability of orally administered LMN-401.
You may be eligible for the study if you meet the following criteria.
Estimated study duration of the main protocol (i.e., start of screening through data analysis) is anticipated to be approximately 12 months. The estimated time it will take for each individual study participant to complete all study visits is anticipated to be up to 6 months (4 visits).
Please contact CDH Research Institute on 07 5408 0900 for additional information or use the email link below. You can also share details of this study to social media via the links below?
Clinical trials are important because they serve as the foundation for most medical advances.